Q1 2023 13F Holders as of 3/31/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
47.9M
-
Number of holders
-
293
-
Total 13F shares, excl. options
-
49.8M
-
Shares change
-
+97.4K
-
Total reported value, excl. options
-
$4.12B
-
Value change
-
+$10.7M
-
Put/Call ratio
-
0.58
-
Number of buys
-
151
-
Number of sells
-
-143
-
Price
-
$82.75
Significant Holders of HAEMONETICS CORP - Common Stock (HAE) as of Q1 2023
340 filings reported holding HAE - HAEMONETICS CORP - Common Stock as of Q1 2023.
HAEMONETICS CORP - Common Stock (HAE) has 293 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 49.8M shares
.
Largest 10 shareholders include Capital Research Global Investors (6.65M shares), BlackRock Inc. (5.78M shares), VANGUARD GROUP INC (5.32M shares), NEUBERGER BERMAN GROUP LLC (3.66M shares), WELLINGTON MANAGEMENT GROUP LLP (3.58M shares), FMR LLC (1.86M shares), STATE STREET CORP (1.73M shares), FRANKLIN RESOURCES INC (1.42M shares), SCHRODER INVESTMENT MANAGEMENT GROUP (946K shares), and GEODE CAPITAL MANAGEMENT, LLC (944K shares).
This table shows the top 293 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.